Login Register Cart 0
Current Medicinal Chemistry

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Translate in Chinese
Research Article

Identification of Ferroptosis-Related Prognostic Models and FDFT1 as a Potential Ferroptosis Driver in Colorectal Cancer

Author(s): Lili Duan, Lu Cao, Jinqiang Liu, Zixiang Wang, Jie Liang, Fan Feng*, Jian Zhang*, Liu Hong* and Jianyong Zheng*

Volume 33, Issue 1, 2026

Published on: 13 February, 2025

Page: [76 - 101] Pages: 26

DOI: 10.2174/0109298673377428250131112647

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Aims: We aimed to develop Ferroptosis-Related Gene (FRG) signatures to predict overall survival (OS) along with disease-free survival (DFS) in individuals with colorectal cancer (CRC).

Background: Prediction of CRC prognosis is challenging. Ferroptosis constitutes a newly reported kind of cell death, and its association with CRC prognosis remains unexplored.

Objective: This research endeavored to establish a prognostic risk signature for colorectal cancer by leveraging ferroptosis-related genes (FRGs), with the objective of refining prognostic precision in clinical settings.

Methods: The clinical data and mRNA expression profiles were obtained from The Cancer Genome Atlas (TCGA) colorectal cancer cohorts. The Lasso algorithm was employed to develop the overall survival (OS) and disease-free survival (DFS) prediction models. These models were subsequently validated using independent data from GSE38832.

Results: Our research unveiled a significant difference in the expression levels of 85% of ferroptosis- related genes (FRGs) between CRC tissues and paracancer tissues. Out of these, 11 prognostic genes were pinpointed through univariate Cox analysis. By employing two models, patients were stratified into low- and high-risk groups based on predicted risk scores, which were subsequently validated as independent prognostic factors via multivariate Cox analysis. The robustness of these models was further confirmed through Receiver Operating Characteristic (ROC) curve analysis. Functional enrichment analysis indicated a predominance of cancer-associated pathways in the high-risk group, including WNT signaling, along with variations in immune status between the two risk categories. Leveraging the Connectivity Map (CMap) database, a total of sixteen potential therapeutic drugs were identified. Additionally, in vitro experiments corroborated that Farnesyl-Diphosphate Farnesyltransferase 1 (FDFT1) was underexpressed in CRC and exhibited tumor suppressive properties. More specifically, FDFT1 may augment ferroptosis in CRC by modulating the expression of the Iron-- Sulfur Cluster Assembly Enzyme (ISCU).

Conclusion: Our study highlighted the significance of ferroptosis-related genes in the pathogenesis of CRC and underscored the potential of ferroptosis-related gene-based risk signatures as valuable tools for improving prognostic accuracy and tailoring therapeutic strategies. However, the validity of these predictive models required further validation through real-world studies to ensure their reliability and applicability.

Keywords: Colorectal cancer, ferroptosis, bioinformatics, prognosis, FDFT1, disease-free survival.

« Previous Next »
[1]
Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2024, 74(3), 229-263.
[http://dx.doi.org/10.3322/caac.21834] [PMID: 38572751]
[2]
Guven, D.C.; Sahin, T.K.; Erul, E.; Rizzo, A.; Ricci, A.D.; Aksoy, S.; Yalcin, S. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci., 2022, 91039121
[http://dx.doi.org/10.3389/fmolb.2022.1039121] [PMID: 36533070]
[3]
Rizzo, A.; Santoni, M.; Mollica, V.; Logullo, F.; Rosellini, M.; Marchetti, A.; Faloppi, L.; Battelli, N.; Massari, F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol., 2021, 17(12), 1455-1466.
[http://dx.doi.org/10.1080/17425255.2021.2029405] [PMID: 35029519]
[4]
Guven, D.C.; Erul, E.; Kaygusuz, Y.; Akagunduz, B.; Kilickap, S.; De Luca, R.; Rizzo, A. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Supp. Care Canc., 2023, 31(12), 624.
[http://dx.doi.org/10.1007/s00520-023-08083-w] [PMID: 37819422]
[5]
Brandi, G.; Ricci, A.D.; Rizzo, A.; Zanfi, C.; Tavolari, S.; Palloni, A.; De Lorenzo, S.; Ravaioli, M.; Cescon, M. Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? Cancer Commun. (Lond.), 2020, 40(9), 461-464.
[http://dx.doi.org/10.1002/cac2.12072] [PMID: 32762027]
[6]
Keum, N.; Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(12), 713-732.
[http://dx.doi.org/10.1038/s41575-019-0189-8] [PMID: 31455888]
[7]
Sahin, T.K.; Ayasun, R.; Rizzo, A.; Guven, D.C. Prognostic Value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel), 2024, 16(21), 3689.
[http://dx.doi.org/10.3390/cancers16213689] [PMID: 39518127]
[8]
Zhao, L.; Zhou, X.; Xie, F.; Zhang, L.; Yan, H.; Huang, J.; Zhang, C.; Zhou, F.; Chen, J.; Zhang, L. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. (Lond.), 2022, 42(2), 88-116.
[http://dx.doi.org/10.1002/cac2.12250] [PMID: 35133083]
[9]
Wang, Y.; Wu, X.; Ren, Z.; Li, Y.; Zou, W.; Chen, J.; Wang, H. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist. Updat., 2023, 66, 100916.
[http://dx.doi.org/10.1016/j.drup.2022.100916] [PMID: 36610291]
[10]
Rodriguez, R.; Schreiber, S.L.; Conrad, M. Persister cancer cells: Iron addiction and vulnerability to ferroptosis. Mol. Cell, 2022, 82(4), 728-740.
[http://dx.doi.org/10.1016/j.molcel.2021.12.001] [PMID: 34965379]
[11]
Yan, H.; Talty, R.; Johnson, C.H. Targeting ferroptosis to treat colorectal cancer. Trends Cell Biol., 2023, 33(3), 185-188.
[http://dx.doi.org/10.1016/j.tcb.2022.11.003] [PMID: 36473802]
[12]
Lei, S.; Chen, C.; Han, F.; Deng, J.; Huang, D.; Qian, L.; Zhu, M.; Ma, X.; Lai, M.; Xu, E.; Zhang, H. AMER1 deficiency promotes the distant metastasis of colorectal cancer by inhibiting SLC7A11- and FTL-mediated ferroptosis. Cell Rep., 2023, 42(9)113110
[http://dx.doi.org/10.1016/j.celrep.2023.113110] [PMID: 37682704]
[13]
Chen, C.; Yang, Y.; Guo, Y.; He, J.; Chen, Z.; Qiu, S.; Zhang, Y.; Ding, H.; Pan, J.; Pan, Y. CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer. Cell Death Dis., 2023, 14(4), 271.
[http://dx.doi.org/10.1038/s41419-023-05803-2] [PMID: 37059712]
[14]
Yang, J.; Mo, J.; Dai, J.; Ye, C.; Cen, W.; Zheng, X.; Jiang, L.; Ye, L. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis., 2021, 12(11), 1079.
[http://dx.doi.org/10.1038/s41419-021-04367-3] [PMID: 34775496]
[15]
Wang, J.; Chen, J.; Wan, L.; Shao, J.; Lu, Y.; Zhu, Y.; Ou, M.; Yu, S.; Chen, H.; Jia, L. Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). AAPS J., 2014, 16(2), 289-298.
[http://dx.doi.org/10.1208/s12248-013-9559-2] [PMID: 24442753]
[16]
Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascón, S.; Hatzios, S.K.; Kagan, V.E.; Noel, K.; Jiang, X.; Linkermann, A.; Murphy, M.E.; Overholtzer, M.; Oyagi, A.; Pagnussat, G.C.; Park, J.; Ran, Q.; Rosenfeld, C.S.; Salnikow, K.; Tang, D.; Torti, F.M.; Torti, S.V.; Toyokuni, S.; Woerpel, K.A.; Zhang, D.D. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017, 171(2), 273-285.
[http://dx.doi.org/10.1016/j.cell.2017.09.021] [PMID: 28985560]
[17]
Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 2015, 43(7), e47.
[http://dx.doi.org/10.1093/nar/gkv007] [PMID: 25605792]
[18]
Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; Jensen, L.J.; Mering, C. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res., 2019, 47(D1), D607-D613.
[http://dx.doi.org/10.1093/nar/gky1131] [PMID: 30476243]
[19]
Simon, N.; Friedman, J.; Hastie, T.; Tibshirani, R. Regularization paths for cox’s proportional hazards model via coordinate descent. J. Stat. Softw., 2011, 39(5), 1-13.
[http://dx.doi.org/10.18637/jss.v039.i05] [PMID: 27065756]
[20]
Chu, M.; Huang, J.; Wang, Q.; Fang, Y.; Cui, D.; Jin, Y. A circadian rhythm-related signature to predict prognosis, immunei infiltration, and drug response in breast cancer. Curr. Med. Chem., 2024, 32(3), 608-626.
[http://dx.doi.org/10.2174/0109298673320179240803071001] [PMID: 39279697]
[21]
Kanehisa, M.; Furumichi, M.; Sato, Y.; Kawashima, M.; Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res., 2023, 51(D1), D587-D592.
[http://dx.doi.org/10.1093/nar/gkac963] [PMID: 36300620]
[22]
Liang, W.; Zhang, L.; Jiang, G.; Wang, Q.; Liu, L.; Liu, D.; Wang, Z.; Zhu, Z.; Deng, Q.; Xiong, X.; Shao, W.; Shi, X.; He, J. Development and validation of a nomogram for predicting survival in patients with resected non-small- cell lung cancer. J. Clin. Oncol., 2015, 33(8), 861-869.
[http://dx.doi.org/10.1200/JCO.2014.56.6661] [PMID: 25624438]
[23]
Lamb, J.; Crawford, E.D.; Peck, D.; Modell, J.W.; Blat, I.C.; Wrobel, M.J.; Lerner, J.; Brunet, J.P.; Subramanian, A.; Ross, K.N.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S.A.; Haggarty, S.J.; Clemons, P.A.; Wei, R.; Carr, S.A.; Lander, E.S.; Golub, T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313(5795), 1929-1935.
[http://dx.doi.org/10.1126/science.1132939] [PMID: 17008526]
[24]
Wang, W.; Green, M.; Choi, J.E.; Gijón, M.; Kennedy, P.D.; Johnson, J.K.; Liao, P.; Lang, X.; Kryczek, I.; Sell, A.; Xia, H.; Zhou, J.; Li, G.; Li, J.; Li, W.; Wei, S.; Vatan, L.; Zhang, H.; Szeliga, W.; Gu, W.; Liu, R.; Lawrence, T.S.; Lamb, C.; Tanno, Y.; Cieslik, M.; Stone, E.; Georgiou, G.; Chan, T.A.; Chinnaiyan, A.; Zou, W. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019, 569(7755), 270-274.
[http://dx.doi.org/10.1038/s41586-019-1170-y] [PMID: 31043744]
[25]
Duan, L.; Yang, W.; Wang, X.; Zhou, W.; Zhang, Y.; Liu, J.; Zhang, H.; Zhao, Q.; Hong, L.; Fan, D. Advances in prognostic markers for colorectal cancer. Expert Rev. Mol. Diagn., 2019, 19(4), 313-324.
[http://dx.doi.org/10.1080/14737159.2019.1592679] [PMID: 30907673]
[26]
Jiang, X.; Stockwell, B.R.; Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol., 2021, 22(4), 266-282.
[http://dx.doi.org/10.1038/s41580-020-00324-8] [PMID: 33495651]
[27]
Hassannia, B.; Vandenabeele, P.; Vanden Berghe, T. Targeting ferroptosis to iron out cancer. Cancer Cell, 2019, 35(6), 830-849.
[http://dx.doi.org/10.1016/j.ccell.2019.04.002] [PMID: 31105042]
[28]
Lei, G.; Zhuang, L.; Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer, 2022, 22(7), 381-396.
[http://dx.doi.org/10.1038/s41568-022-00459-0] [PMID: 35338310]
[29]
Zheng, Z.; Li, Y.; Jin, G.; Huang, T.; Zou, M.; Duan, S. The biological role of arachidonic acid 12-lipoxygenase (ALOX12) in various human diseases. Biomed. Pharmacoth., 2020, 129, 110354.
[http://dx.doi.org/10.1016/j.biopha.2020.110354] [PMID: 32540644]
[30]
Ruan, G.T.; Gong, Y.Z.; Zhu, L.C.; Gao, F.; Liao, X.W.; Wang, X.K.; Zhu, G.Z.; Liao, C.; Wang, S.; Yan, L.; Xie, H.L.; Zhou, X.; Liu, J.Q.; Shao, M.N.; Gan, J.L. The perspective of diagnostic and prognostic values of lipoxygenases mRNA expression in colon adenocarcinoma. OncoTargets Ther., 2020, 13, 9389-9405.
[http://dx.doi.org/10.2147/OTT.S251965] [PMID: 33061426]
[31]
Zeng, C.M.; Chang, L.L.; Ying, M.D.; Cao, J.; He, Q.J.; Zhu, H.; Yang, B. Aldo–Keto reductase AKR1C1– AKR1C4: functions, regulation, and intervention for anti-cancer therapy. Front. Pharmacol., 2017, 8, 119.
[http://dx.doi.org/10.3389/fphar.2017.00119] [PMID: 28352233]
[32]
Gagliardi, M.; Cotella, D.; Santoro, C.; Corà, D.; Barlev, N.A.; Piacentini, M.; Corazzari, M. Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis., 2019, 10(12), 902.
[http://dx.doi.org/10.1038/s41419-019-2143-7] [PMID: 31780644]
[33]
Matsunaga, T.; Hojo, A.; Yamane, Y.; Endo, S.; El-Kabbani, O.; Hara, A. Pathophysiological roles of aldo–keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem. Biol. Interact., 2013, 202(1-3), 234-242.
[http://dx.doi.org/10.1016/j.cbi.2012.09.024] [PMID: 23165153]
[34]
Weng, M.; Chen, W.; Chen, X.; Lu, H.; Sun, Z.; Yu, Q.; Sun, P.; Xu, Y.; Zhu, M.; Jiang, N.; Zhang, J.; Zhang, J.; Song, Y.; Ma, D.; Zhang, X.; Miao, C. Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression. Nat. Commun., 2020, 11(1), 1869.
[http://dx.doi.org/10.1038/s41467-020-15795-8] [PMID: 32313017]
[35]
Huang, R.; Zhang, C.; Wang, X.; Zou, X.; Xiang, Z.; Wang, Z.; Gui, B.; Lin, T.; Hu, H. Identification of FDFT1 as a potential biomarker associated with ferroptosis in ccRCC. Cancer Med., 2022, 11(21), 3993-4004.
[http://dx.doi.org/10.1002/cam4.4716] [PMID: 35322581]
[36]
Ye, L.; Zhang, T.; Kang, Z.; Guo, G.; Sun, Y.; Lin, K.; Huang, Q.; Shi, X.; Ni, Z.; Ding, N.; Zhao, K.N.; Chang, W.; Wang, J.; Lin, F.; Xue, X. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front. Immunol., 2019, 10, 2368.
[http://dx.doi.org/10.3389/fimmu.2019.02368] [PMID: 31681276]
[37]
Zhang, J.; Liu, J.; Wu, J.; Li, W.; Chen, Z.; Yang, L. Progression of the role of CRYAB in signaling pathways and cancers. OncoTargets Ther., 2019, 12, 4129-4139.
[http://dx.doi.org/10.2147/OTT.S201799] [PMID: 31239701]
[38]
Shi, C.; He, Z.; Hou, N.; Ni, Y.; Xiong, L.; Chen, P. Alpha B-crystallin correlates with poor survival in colorectal cancer. Int. J. Clin. Exp. Pathol., 2014, 7(9), 6056-6063.
[PMID: 25337251]
[39]
Shi, C.; Yang, X.; Bu, X.; Hou, N.; Chen, P. Alpha B-crystallin promotes the invasion and metastasis of colorectal cancer via epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun., 2017, 489(4), 369-374.
[http://dx.doi.org/10.1016/j.bbrc.2017.05.070] [PMID: 28506831]
[40]
Sun, L.; Wan, A.; Zhou, Z.; Chen, D.; Liang, H.; Liu, C.; Yan, S.; Niu, Y.; Lin, Z.; Zhan, S.; Wang, S.; Bu, X.; He, W.; Lu, X.; Xu, A.; Wan, G. RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut, 2021, 70(9), 1698-1712.
[http://dx.doi.org/10.1136/gutjnl-2020-320652] [PMID: 33219048]
[41]
Gao, M.; Monian, P.; Pan, Q.; Zhang, W.; Xiang, J.; Jiang, X. Ferroptosis is an autophagic cell death process. Cell Res., 2016, 26(9), 1021-1032.
[http://dx.doi.org/10.1038/cr.2016.95] [PMID: 27514700]
[42]
Sebastián, V.P.; Salazar, G.A.; Coronado-Arrázola, I.; Schultz, B.M.; Vallejos, O.P.; Berkowitz, L.; Álvarez-Lobos, M.M.; Riedel, C.A.; Kalergis, A.M.; Bueno, S.M. Heme oxygenase-1 as a modulator of intestinal inflammation development and progression. Front. Immunol., 2018, 9, 1956.
[http://dx.doi.org/10.3389/fimmu.2018.01956] [PMID: 30258436]
[43]
Andrés, N.C.; Fermento, M.E.; Gandini, N.A.; Romero, A.L.; Ferro, A.; Donna, L.G.; Curino, A.C.; Facchinetti, M.M. Heme oxygenase-1 has antitumoral effects in colorectal cancer: Involvement of p53. Exp. Mol. Pathol., 2014, 97(3), 321-331.
[http://dx.doi.org/10.1016/j.yexmp.2014.09.012] [PMID: 25236576]
[44]
Zhang, M.; Miao, F.; Huang, R.; Liu, W.; Zhao, Y.; Jiao, T.; Lu, Y.; Wu, F.; Wang, X.; Wang, H.; Zhao, H.; Ju, H.; Miao, S.; Wang, L.; Song, W. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1. J. Exp. Clin. Cancer Res., 2018, 37(1), 22.
[http://dx.doi.org/10.1186/s13046-018-0687-5] [PMID: 29426364]
[45]
de Barrios, O.; Sanchez-Moral, L.; Cortés, M.; Ninfali, C.; Profitós-Pelejà, N.; Martínez-Campanario, M.C.; Siles, L.; del Campo, R.; Fernández-Aceñero, M.J.; Darling, D.S.; Castells, A.; Maurel, J.; Salas, A.; Dean, D.C.; Postigo, A. ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells. Gut, 2019, 68(12), 2129-2141.
[http://dx.doi.org/10.1136/gutjnl-2018-317294] [PMID: 31366457]
[46]
Lu, X.Y.; Shi, X.J.; Hu, A.; Wang, J.Q.; Ding, Y.; Jiang, W.; Sun, M.; Zhao, X.; Luo, J.; Qi, W.; Song, B.L. Feeding induces cholesterol biosynthesis via the mTORC1–USP20–HMGCR axis. Nature, 2020, 588(7838), 479-484.
[http://dx.doi.org/10.1038/s41586-020-2928-y] [PMID: 33177714]
[47]
Sharma, B.; Gupta, V.; Dahiya, D.; Kumar, H.; Vaiphei, K.; Agnihotri, N. Clinical relevance of cholesterol homeostasis genes in colorectal cancer. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2019, 1864(10), 1314-1327.
[http://dx.doi.org/10.1016/j.bbalip.2019.06.008] [PMID: 31202724]
[48]
Zhang, L.; Liu, W.; Liu, F.; Wang, Q.; Song, M.; Yu, Q.; Tang, K.; Teng, T.; Wu, D.; Wang, X.; Han, W.; Li, Y. Corrigendum to “IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/MTOR pathway in colorectal cancer”. Oxid. Med. Cell. Longev., 2020, 2020, 1-2.
[http://dx.doi.org/10.1155/2020/6901472] [PMID: 32322334]
[49]
Saxton, R.A.; Sabatini, D.M. mTOR signaling in growth, metabolism, and disease. Cell, 2017, 168(6), 960-976.
[http://dx.doi.org/10.1016/j.cell.2017.02.004] [PMID: 28283069]
[50]
Kang, R.; Kroemer, G.; Tang, D. The tumor suppressor protein p53 and the ferroptosis network. Free Radic. Biol. Med., 2019, 133, 162-168.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.05.074] [PMID: 29800655]
[51]
Calais, G.; Hirst, D.G. In situ tumour radio sensitization induced by clofibrate administration: single dose and fractionated studies. Radiother. Oncol., 1991, 22(2), 99-103.
[http://dx.doi.org/10.1016/0167-8140(91)90004-Z] [PMID: 1957008]
[52]
Lei, G.; Zhang, Y.; Koppula, P.; Liu, X.; Zhang, J.; Lin, S.H.; Ajani, J.A.; Xiao, Q.; Liao, Z.; Wang, H.; Gan, B. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res., 2020, 30(2), 146-162.
[http://dx.doi.org/10.1038/s41422-019-0263-3] [PMID: 31949285]
[53]
Gelfo, V.; Pontis, F.; Mazzeschi, M.; Sgarzi, M.; Mazzarini, M.; Solmi, R.; D’Uva, G.; Lauriola, M. Glucocorticoid receptor modulates EGFR feedback upon acquisition of resistance to monoclonal antibodies. J. Clin. Med., 2019, 8(5), 600.
[http://dx.doi.org/10.3390/jcm8050600] [PMID: 31052457]
[54]
Khambata-Ford, S.; Garrett, C.R.; Meropol, N.J.; Basik, M.; Harbison, C.T.; Wu, S.; Wong, T.W.; Huang, X.; Takimoto, C.H.; Godwin, A.K.; Tan, B.R.; Krishnamurthi, S.S.; Burris, H.A., III; Poplin, E.A.; Hidalgo, M.; Baselga, J.; Clark, E.A.; Mauro, D.J. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol., 2007, 25(22), 3230-3237.
[http://dx.doi.org/10.1200/JCO.2006.10.5437] [PMID: 17664471]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 78
Html icon 1
Find your institution